Clinical trials: Complete Pathological Response
Breast Cancer
Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer
This prospective cohort study aims to identify immune-related predictive factors of response to neoadjuvant chemotherapy in patients with early breast cancer.
- Trial name
- AKRA (NCT07407244)
- Testing
- Neoadjuvant Chemotherapy
- Where
- Slovenia
- Volunteers
- 268 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer
In this study, investigators utilize a radiomics prediction model to predict the tumor response to neoadjuvant chemoradiotherapy (nCRT) before the nCRT is administered for patients with locally advanced rectal cancer (LARC).
- Trial name
- MRAI-pCR (NCT04273477)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Upper Respiratory Infections
Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting
The purpose of this study is to assess the accuracy and ease-of-use of a simplified FilmArray Respiratory Panel test (FilmArray RP EZ) when performed according to the manufacturer's instructions by personnel in laboratories…
- Trial name
- NCT02232711
- Where
- 4 sites in United States
- Volunteers
- 1,082 people
- Sponsor
- BioFire Diagnostics, LLC
Uterine Cervical Neoplasms, Locally Advanced
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Purpose: To evaluate the efficacy and safety of neoadjuvant treatment with iparomlimab and tuvonralimab (QL1706), a dual PD1and CTLA4 bispecific antibody, in combination with paclitaxel and either cisplatin or carboplatin (TP/TC…
- Trial name
- QUARTZ-CC (NCT07646301)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as…
- Trial name
- NCT01134484
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Michele Cavo
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma
Perioperative chemotherapy with the FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is a standard treatment for resectable gastric and gastroesophageal junction adenocarcinoma.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
- Trial name
- NCT07859254
- Testing
- FLOT Chemotherapy
- Where
- Colombia
- Volunteers
- 90 people
- Sponsor
- Fundación Santa Fe de Bogota
Breast Cancer, Neoadjuvant Therapy
Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer
This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer.
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Pathological Response, Invasive Breast Carcinoma
- Trial name
- miRNA-NAC (NCT07289282)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Atlas University
Non-small Cell Lung Cancer
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with.
- Trial name
- NCT07672223
- Testing
- SYS6010, Enlonstobart, Tislelizumab
- Volunteers
- 570 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Triple Negative Breast Cancer
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
[Background]: Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2 (HER-2).
- Trial name
- NCT02511847
- Testing
- Afatinib
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rectal Cancer
Validation of a Predictive Model After Complete Response in Rectal Cancer
Background of the study: Prediction of rectal tumor response after chemoradiotherapy (CRT) might be helpful in individualizing treatment strategies, i.e., selecting patients who need less invasive surgery or another radiotherapy…
- Trial name
- Thunder (NCT00969657)
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht Radiation Oncology
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)
The main goal of the study is to abandon breast surgery in patients with breast cancer with a clinical complete response (cCR) after neoadjuvant systemic therapy and confirmed pCR using Vacuum-assisted biopsy (VAB) and sentinel…
- Trial name
- VAB (NCT04293796)
- Testing
- Vacuum-assisted biopsy
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
- Trial name
- OLN-EME (NCT04232423)
- Testing
- Olanzapine 10 Mg ORAL TABLET, Olanzapine 5 Mg ORAL TABLET
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Non Small Cell Lung Cancer
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response
A total of 58 patients were enrolled in this exploratory study and randomly assigned to cohort 1 and cohort 2, with 29 patients in each group.
- Trial name
- NCT06851169
- Testing
- Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib), Cohort 2: Neoadjuvant therapy (benmelstobart only)
- Volunteers
- 58 people
- Sponsor
- Tang-Du Hospital
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Gastroesophageal Reflux Disease
Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)
The aim of this study is to evaluate the complete remission rates, endoscopic relapses, study discontinuation rates, and quality of life parameters in patients with erosive GERD.
- Trial name
- NCT00325676
- Testing
- Pantoprazole
- Where
- 45 sites in Brazil, Germany and 2 more
- Volunteers
- 639 people
- Sponsor
- Takeda
Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free…
- Conditions
- Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response
- Trial name
- THUNDER2 (NCT04815694)
- Testing
- RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Staphylococcal Bacteraemia
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with…
- Trial name
- NCT04775953
- Testing
- Cefazolin, Dalbavancin, Daptomycin
- Where
- 24 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)